Lab Discovery Could Help Transplanted Insulin-Producing Cells Survive Longer

For people with Type 1 diabetes, transplantation of insulin-producing islets offers promise for improving blood sugar control. However, this treatment faces a major hurdle: the transplanted beta cells—the insulin factories inside islets—die rapidly after being placed into the recipient's body. This loss of cell function and survival happens so quickly that it significantly limits how well the transplant works long-term.

Researchers have discovered that a type of support cell called mesenchymal stromal cells (MSCs) can dramatically improve the survival of transplanted islets. When MSCs are placed alongside islet cells—either in laboratory dishes or during transplantation—the beta cells stay healthier and functional. Until now, scientists didn't fully understand the mechanism behind this protection.

The new research reveals that MSCs don't need to be present themselves to help. Instead, they release tiny particles called extracellular vesicles (EVs) that do much of the protective work. These vesicles are like microscopic cargo containers filled with proteins and genetic molecules that communicate with beta cells and help them survive.

Using advanced laboratory techniques, researchers analyzed what's packed inside MSC-derived vesicles. They found over 100 different proteins, including molecules known to enhance beta cell function and survival. The vesicles also carry approximately 300 distinct microRNAs—tiny regulatory molecules that control how genes are expressed in cells.

Five of these microRNAs were particularly abundant and active in treated islets, suggesting they play key roles in protecting beta cells. The vesicles also altered the expression of multiple genes involved in how islets metabolize glucose and produce insulin.

Because extracellular vesicles alone can replicate many of the benefits MSCs provide, this opens the door to simpler, cell-free treatments. Instead of transplanting living MSC cells—which come with their own complexities and regulatory challenges—doctors might eventually use purified vesicles or the specific molecules they contain.

Researchers suggest this approach could be further refined by focusing on individual, biologically active molecules within the vesicles that can be manufactured to pharmaceutical-grade standards. This could eventually lead to standardized medicines designed to protect transplanted islets, rather than relying on cell-based therapies.

While this research is early-stage and performed in laboratory settings, it represents an important step toward understanding how to improve islet transplant outcomes and potentially expand access to this beneficial treatment for people with Type 1 diabetes.

Source: Cells. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.